tickdelta
Sign in
Screener / SEC EDGAR /CIK 0001551152 /10-K filed Feb 20, 2026, compared with Feb 14, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
HCAMRKABBVBMYPFEABT
NYSE Health care · Pharmaceuticals

AbbVie ABBV

ABBV quote by TradingView

AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. 10-K, Item 1

Employees
57,000
Headquarters
North Chicago, IL
Next results
around Jan 6, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $61.2B through the costs to a net profit of $4.2B · income statement of the 10-K

25% operating margin
Revenue to Gross profit: $43.0BRevenue to Cost of revenue: $18.2BGross profit to Operating profit: $15.1BGross profit to Operating expenses: $27.9BOperating profit to Net profit: $4.2BOperating profit to Tax & other: $10.8BOperating expenses to R&D: $9.1BOperating expenses to Sales, admin & other: $18.8B Revenue: $61.2B REVENUE $61.2B +9% Y/Y Gross profit: $43.0B · 70% margin GROSS PROFIT $43.0B 70% margin Cost of revenue: $18.2B · 30% of revenue COST OF REVENUE $18.2B 30% of revenue Operating profit: $15.1B · 25% margin OPERATING PROFIT $15.1B 25% margin · +65% Y/Y Operating expenses: $27.9B · 46% of revenue OPERATING EXPENSES $27.9B 46% of revenue Net profit: $4.2B · 7% margin NET PROFIT $4.2B 7% margin · −1% Y/Y Tax & other: $10.8B · 18% of revenue TAX & OTHER $10.8B 18% of revenue R&D: $9.1B · 15% of revenue R&D $9.1B 15% of revenue Sales, admin & other: $18.8B · 31% of revenue SALES, ADMIN & OTHER $18.8B 31% of revenue
Gross profit $43.0B 70% margin
Operating profit $15.1B 25% margin · +65% Y/Y
Net profit $4.2B 7% margin · −1% Y/Y
The full income statement, year by year

ABBV among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 8.6%, above 59% of 59 peers (their median 7.1%) REVENUE GROWTH 8.6% · above 59% Gross margin: 73.7%, above 82% of 50 peers (their median 64.2%) GROSS MARGIN 73.7% · above 82% Operating margin: 32.2%, above 92% of 50 peers (their median 13.4%) OPERATING MARGIN 32.2% · above 92% Net margin: 15.7%, above 69% of 59 peers (their median 9.5%) NET MARGIN 15.7% · above 69% FCF margin: 28.6%, above 96% of 55 peers (their median 15.2%) FCF MARGIN 28.6% · above 96%
ABBV Peer median Below the median

What changed

8 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 20, 2026 against Feb 14, 2025.

Risk factors
8 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Material impairment (8-K item 2.06)
8-K item 2.06 (material impairments) filed Jan 10, 2025
10-K · XBRL
Accounting checks
10 other checks clear, 1 worth a look
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
4 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Material impairment (8-K item 2.06)
    8-K item 2.06 (material impairments) filed Jan 10, 2025
  • Receivables +15.3% vs revenue +8.6% (+6.7 pts)
9 more checks with nothing to note
  • Cash from operations $19.0B vs net income $4.2B (FY ending Dec 31, 2025)
  • Inventory +18.4% vs revenue +8.6% (+9.8 pts)
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No longer listed: Valuation of contingent consideration. Same as last year: Sales rebate accruals for Medicaid, Medicare and managed care programs
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 1.03 in the last 2 years

In their words

8 paragraphs in Risk Factors that were not in the 10-K filed Feb 14, 2025. Quoted as filed.

All 8 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 14, 2025 10-K, ITEM 1A
    In addition to the pricing mechanisms established under the IRA, governments and other payers may pursue or implement additional approaches intended to reduce pharmaceutical costs, including arrangements or frameworks that reference international prices, most-favored-nation (MFN) concepts, or other comparative pricing methodologies.…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 14, 2025 10-K, ITEM 1A
    Pharmacy benefit managers and other supply chain intermediaries exert significant influence over pricing and patient access to our products, which could adversely affect our revenues and results of operations. Consolidation and vertical integration among PBMs, managed care organizations and other supply chain intermediaries has…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 14, 2025 10-K, ITEM 1A
    Trade restrictions, tariffs, and other changes in global trade policy could increase costs, disrupt supply chains, and adversely affect AbbVie’s business and results of operations. AbbVie operates in a global environment and relies on complex international supply chains for the development, manufacture, and distribution of its products,…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$58.1B$54.3B$56.3B$61.2B
Net income$11.8B$4.9B$4.3B$4.2B
Operating cash flow$24.9B$22.8B$18.8B$19.0B
Free cash flow$24.2B$22.1B$17.8B$17.8B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$61.2B ▲ 8.6% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

AbbVie, North Chicago, IL · from the 10-K filed Feb 20, 2026

AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as Chief Operating Decision Maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, development, manufacturing and supply of products.

Headquarters
North Chicago, IL
Country
United States
Listed on
NYSE
Fiscal year ends
December 31
Last results
Oct 30, 2026
Incorporated in
DE

Employees, at the top of the page: "AbbVie employed approximately 57,000 employees in over 70 countries as of December 31, 2025" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 20, 2026 (open at SEC), compared with the 10-K filed Feb 14, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ABBV/export.csv") into a cell.